Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: Evidence for waning immunity

Eurosurveillance

Volumn 24, Issue 17, 2019, Pages

  Bitzegeio, Julia ^a,b   Majowicz, Shannon ^c   Matysiak Klose, Dorothea ^d   Sagebiel, Daniel ^a   Werber, Dirk ^a  

^a Unit for Surveillance and Epidemiology of Infectious Diseases   (Germany)

^b Berlin School of Public Health   (Germany)

^c UNIVERSITY OF WATERLOO   (Canada)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; VIRUS ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; EPIDEMIC; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MONTE CARLO METHOD; VACCINATION COVERAGE; ADOLESCENT; AGE; BLOOD; IMMUNIZATION; IMMUNOLOGY; MEASLES VIRUS; PATHOGENICITY; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; ANTIBODIES, VIRAL; BERLIN; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; GERMANY; HUMANS; IMMUNIZATION SCHEDULE; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; RETROSPECTIVE STUDIES; VACCINATION; VACCINATION COVERAGE; YOUNG ADULT;

EID: 85065503038     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2019.24.17.1800529     Document Type: Article

References (31)

1. Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. Nat Rev Dis Primers. 2016;2:16049. https://doi.org/10.1038/nrdp.2016.49 PMID: 27411684
2. World Health Organization (WHO). Global eradication of measles: 63rd World Health Assembly. Geneva: WHO; 2010. Available from: http://apps.who.int/gb/ebwha/pdf_files/wha63/a63_18-en.pdf
3. World Health Organization, Regional Office for Europe. (WHO/Euro). Eliminating measles and rubella - Framework for the verification process in the WHO European Region. Copenhagen:WHO/Euro; 2014. Available from: http://www.euro.who. int/__data/assets/pdf_file/0009/247356/Eliminating-measlesand- rubella-Framework-for-the-verification-process-in-the-WHO-European-Region.pdf?ua=1
4. German Ministry of Health. Nationaler Aktionsplan 2015-2020 zur Elimination der Masern und Röteln in Deutschland [National Action Plan 2015-2020 on elimination of measles and rubella in Germany]. Berlin: Ministry of Health; 2015. German. Available from: https://www.gmkonline.de/documents/Aktionsplan_Masern_Roeteln_2.pdf.
5. World Health Organization (WHO). WHO measles vaccines:WHO position paper - April 2017 Geneva: WHO; 2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/255149/WER9217.pdf?sequence=1
6. Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis. 2004;189(s1) Suppl 1;S27-35. PMID: 15106086
7. Takla A, Wichmann O, Rieck T, Matysiak-Klose D. Measles incidence and reporting trends in Germany, 2007-2011. Bull World Health Organ. 2014;92(10):742-9. https://doi. org/10.2471/BLT.13.135145 PMID: 25378728
8. Werber D, Hoffmann A, Santibanez S, Mankertz A, Sagebiel D. Large measles outbreak introduced by asylum seekers and spread among the insufficiently vaccinated resident population, Berlin, October 2014 to August 2015. Euro Surveill. 2017;22(34):30599. https://doi.org/10.2807/1560-7917. ES.2017.22.34.30599 PMID: 28857043
9. Hellenbrand W, Siedler A, Tischer A, Meyer C, Reiter S, Rasch G, et al. Progress toward measles elimination in Germany. J Infect Dis. 2003;187(s1) Suppl 1;S208-16. https://doi. org/10.1086/368046 PMID: 12721915
10. Robert Koch Institut (RKI). Epidemiologisches Bulletin 32/2010. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (RKI) [Communication from the Standing Vaccination Commission (STIKO) at the Robert Koch Institute (RKI)]. Berlin: RKI; 2010. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2010/Ausgaben/32_10. pdf?__blob=publicationFile
11. Siedler A, Rieck T, Reuss A, Walter D, Poggensee G, Poethko-Muller C, et al. Estimating vaccination coverage in the absence of immunisation registers--the German experience. Euro Surveill. 2012;17(17):20152. https://doi.org/10.2807/ese.17.17.20152-en PMID: 22551497
12. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197(7):950-6. https://doi.org/10.1086/528993 PMID:18419470
13. LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med. 2007;161(3):294-301. https://doi.org/10.1001/archpedi.161.3.294 PMID: 17339511
14. Mossong J, O’Callaghan CJ, Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine. 2000;19(4-5):523-9. https://doi.org/10.1016/S0264-410X(00)00175-4 PMID: 11027817
15. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22(4):742-6. https://doi.org/10.1093/ije/22.4.742 PMID: 8225751
16. Robert Koch-Institut (RKI). VacMap - Masern-Impfquoten in Deutschland. [VacMap - Measles vaccination coverage in Germany]. Berlin: RKI; [Accessed Sep 2018]. German. Available from: http://www.vacmap.de/
17. Robert Koch-Insitut (RKI). Epidemiologisches Bulletin. [Epidemiological Bulletin]. Berlin: RKI; [Accessed Sep 2018]. German. Available from: https://www.rki.de/SiteGlobals/Forms/Suche/EpidBull/epidbullsuche_formular.html
18. Deeks SL, Lim GH, Simpson MA, Gagné L, Gubbay J, Kristjanson E, et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ. 2011;183(9):1014-20. https://doi.org/10.1503/cmaj.101371 PMID: 21576295
19. Das statistische Informationssystem Berlin Brandenburg. AfS StatIS-BBB - Tabellenansicht. [Statistical Information System Berlin Brandenburg]. Berlin; [Accessed Sep 2018]. German. Available from: https://www.statistik-berlin-brandenburg.de/webapi/jsf/tableView/tableView.xhtml.
20. Schuster M, Stelzer T, Burckhardt F. Why are young adults affected? Estimating measles vaccination coverage in 20-34 year old germans in order to verify progress towards measles elimination. PLoS Curr. 2015;7:ecurrents.outbreaks.0a2d3e946 5f067a0b2933d598d504d2e. PMID: 25789202
21. Poethko-Müller C, Kuhnert R, Schlaud M. Durchimpfung und Determinanten des Impfstatus in Deutschland. Ergebnisse des Kinder- und Jugendgesundheitssurveys (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(5-6):851-62. https://doi. org/10.1007/s00103-007-0248-0 PMID: 17514471
22. Robert Koch Institut (RKI). Epidemiologoshces Bulletin. Impfschutz bei Erwachsenen in Schleswig-Holstein 2011 - ein Update nach acht Jahren: Ergebnisse einer Erhebung verbunden mit den Maßnahmen zur Verbesserung des Impfschutzes durch die Arbeitsmedizinischen Dienste [Vaccination coverage in adults in Schleswig-Holstein 2011 - an update 8 years later: Results of a survey in connection with measurements for improvement in vaccination coverage through occupational health services]. Berlin:RKI; 2013. German. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/22_13. pdf?__blob=publicationFile
23. Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis. 2011;204(Suppl 1):S133-48. https://doi. org/10.1093/infdis/jir102 PMID: 21666154
24. Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, et al. Large measles outbreak at a German public school, 2006. Pediatr Infect Dis J. 2007;26(9):782-6. https://doi.org/10.1097/INF.0b013e318060aca1 PMID: 17721371
25. Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, Muller CP. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol. 1999;150(11):1238-49. https://doi.org/10.1093/oxfordjournals. aje.a009951 PMID: 10588085
26. Farrington CP. The measurement and interpretation of agespecific vaccine efficacy. Int J Epidemiol. 1992;21(5):1014-20. https://doi.org/10.1093/ije/21.5.1014 PMID: 1468838
27. Crowcroft NS, Levy-Bruhl D. Registries: An essential tool for maximising the health benefits of immunisation in the 21st century. Euro Surveill. 2017;22(17):30523. https://doi. org/10.2807/1560-7917.ES.2017.22.17.30523 PMID: 28488997
28. European Centre for Disease Prevention and Control (ECDC). Measles and Rubella Surveillance 2017. Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/sites/portal/files/documents/Measles-and-Rubella-Surveillance-2017.pdf
29. Rosen JB, Rota JS, Hickman CJ, Sowers SB, Mercader S, Rota PA, et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis. 2014;58(9):1205-10. https://doi.org/10.1093/cid/ciu105 PMID:24585562
30. Rota JS, Hickman CJ, Sowers SB, Rota PA, Mercader S, Bellini WJ. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. J Infect Dis. 2011;204(Suppl 1):S559-63. https://doi.org/10.1093/infdis/jir098 PMID: 21666213
31. Chen CJ, Lin TY, Huang YC. Letter to the editor: Occurrence of modified measles during outbreak in Taiwan in 2018. Euro Surveill. 2018;23(37):1800485.